ACRV
Acrivon Therapeutics Inc (ACRV)
Healthcare • NASDAQ • $1.98-2.46%
- Symbol
- ACRV
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.98
- Daily Change
- -2.46%
- Market Cap
- $84.75M
- Trailing P/E
- N/A
- Forward P/E
- -1.06
- 52W High
- $3.56
- 52W Low
- $1.05
- Analyst Target
- $11.50
- Dividend Yield
- N/A
- Beta
- 2.02
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 an…
Company websiteResearch ACRV on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.